# US 12,109,210 B2 · Methods for treating mast cell tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,109,210 B2
- Document ID: US12109210B2
- Status: Granted
- Kind: B2
- Application number: 17/489,353
- Filed: 2021-09-29
- Published: 2023-03-30
- Granted: 2024-10-08
- Earliest claimed: 2021-09-29
- Assignees: Gongwin Biopharm Co., Ltd
- Applicants: Gongwin Biopharm Co., Ltd
- Inventors: Chuan-Ching Yang; Mao-Yuan Lin; Shu-Ying Cheng; Yi-Jhen Feng
- Web page: https://patentgrep.com/patent/US12109210B2

## CPC

- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 35/00: Antineoplastic agents
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a pharmaceutical composition for treating a mast cell tumor, including a benzenesulfonamide derivative and a pharmaceutically acceptable carrier. Also provided is a method for treating a mast cell tumor in a subject in need thereof by using the pharmaceutical composition.

## Claims

### Claim 1

A method for treating a mast cell tumor in a subject in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a benzenesulfonamide derivative and a pharmaceutically acceptable carrier thereof, wherein the benzenesulfonamide derivative is para-toluene sulfonamide, ortho-toluene sulfonamide, or meta-toluene sulfonamide, or a pharmaceutically acceptable salt thereof,
wherein the pharmaceutically acceptable carrier is at least one selected from the group consisting of alkylene glycol, sebacic acid, dimethyl sulfoxide, and any combination thereof, and
wherein the pharmaceutical composition is administered to the subject by an intratumoral injection.

### Claim 2 (depends on 1)

The method of claim 1, wherein the alkylene glycol is at least one selected from the group consisting of polyethylene glycol, propylene glycol, hexylene glycol, and any combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the benzenesulfonamide derivative is present in an amount of from 1% to 50% by weight of the pharmaceutical composition.

### Claim 4 (depends on 3)

The method of claim 3, wherein the benzenesulfonamide derivative is present in an amount of from 20% to 40% by weight of the pharmaceutical composition.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises at least one of 1% to 50% by weight of polyethylene glycol 400, 1% to 10% by weight of 1,2-propylene glycol, 1% to 10% by weight of sebacic acid, 1% to 20% by weight of 2-ethyl-1,3-hexanediol, 0% to 20% by weight of dimethyl sulfoxide, and 0% to 20% by weight of ethanol.

### Claim 6 (depends on 1)

The method of claim 1, wherein the administering causes ablation of the mast cell tumor in the subject.

### Claim 7 (depends on 1)

The method of claim 1, wherein the mast cell tumor is a canine mast cell tumor, a feline mast cell tumor, an equine mast cell tumor, a cattle mast cell tumor, or a sheep mast cell tumor.

### Claim 8 (depends on 1)

The method of claim 1, wherein the mast cell tumor is a cutaneous mast cell tumor or a visceral mast cell tumor.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject is selected from the group consisting of a rodent, a murine, a monkey, a guinea pig, a dog, a cat, a cow, a sheep, a pig, a horse, a rabbit, and a human.

### Claim 10 (depends on 1)

The method of claim 1, wherein the benzenesulfonamide derivative in the pharmaceutical composition is administered to the subject in a therapeutically effective amount of from about 33 mg/day to about 10,000 mg/day.

### Claim 11 (depends on 1)

The method of claim 1, wherein the benzenesulfonamide derivative in the pharmaceutical composition is administered to the subject in a therapeutically amount of from about 165 mg/day to about 3,300 mg/day.

### Claim 12 (depends on 1)

The method of claim 1, wherein the benzenesulfonamide derivative in the pharmaceutical composition is administered to the subject in a therapeutically effective amount of from about 330 mg/day to about 1,650 mg/day.

### Claim 13 (depends on 1)

The method of claim 1, wherein the benzenesulfonamide derivative in the pharmaceutical composition is administered to the subject in a therapeutically effective amount of from about 33 mg to about 26,400 mg during a treatment period or a treatment cycle.